CONMED Valuation
Is EC8 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of EC8 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: EC8 (€66.5) is trading below our estimate of fair value (€130.33)
Significantly Below Fair Value: EC8 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for EC8?
Key metric: As EC8 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is EC8's PE Ratio? | |
|---|---|
| PE Ratio | 16.9x |
| Earnings | US$131.74m |
| Market Cap | US$2.20b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.4x |
| Enterprise Value/EBITDA | 14.2x |
| PEG Ratio | 1.2x |
Price to Earnings Ratio vs Peers
How does EC8's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 22.4x | ||
AFX Carl Zeiss Meditec | 25.7x | 16.3% | €5.2b |
EUZ Eckert & Ziegler | 21.3x | 4.0% | €802.1m |
DRW3 Drägerwerk KGaA | 7.2x | 2.0% | €792.8m |
SBS Stratec | 35.3x | 25.4% | €353.7m |
EC8 CONMED | 16.9x | 13.8% | €2.2b |
Price-To-Earnings vs Peers: EC8 is good value based on its Price-To-Earnings Ratio (16.9x) compared to the peer average (22.4x).
Price to Earnings Ratio vs Industry
How does EC8's PE Ratio compare vs other companies in the European Medical Equipment Industry?
| 3 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 3 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: EC8 is good value based on its Price-To-Earnings Ratio (16.9x) compared to the European Medical Equipment industry average (29.9x).
Price to Earnings Ratio vs Fair Ratio
What is EC8's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 16.9x |
| Fair PE Ratio | 22.9x |
Price-To-Earnings vs Fair Ratio: EC8 is good value based on its Price-To-Earnings Ratio (16.9x) compared to the estimated Fair Price-To-Earnings Ratio (22.9x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €66.50 | €76.43 +14.9% | 12.4% | €93.78 | €66.20 | n/a | 8 |
| Nov ’25 | €62.50 | €76.43 +22.3% | 12.4% | €93.78 | €66.20 | n/a | 8 |
| Oct ’25 | €64.00 | €75.99 +18.7% | 13.6% | €94.52 | €64.87 | n/a | 8 |
| Sep ’25 | €66.50 | €75.99 +14.3% | 13.6% | €94.52 | €64.87 | n/a | 8 |
| Aug ’25 | €61.50 | €75.99 +23.6% | 13.6% | €94.52 | €64.87 | n/a | 8 |
| Jul ’25 | €64.00 | €86.11 +34.5% | 19.3% | €123.05 | €69.92 | n/a | 8 |
| Jun ’25 | €69.50 | €86.11 +23.9% | 19.3% | €123.05 | €69.92 | n/a | 8 |
| May ’25 | €62.50 | €86.11 +37.8% | 19.3% | €123.05 | €69.92 | n/a | 8 |
| Apr ’25 | €74.00 | €102.24 +38.2% | 11.2% | €121.44 | €90.16 | n/a | 8 |
| Mar ’25 | €74.00 | €102.24 +38.2% | 11.2% | €121.44 | €90.16 | n/a | 8 |
| Feb ’25 | €78.50 | €102.24 +30.2% | 11.2% | €121.44 | €90.16 | n/a | 8 |
| Jan ’25 | €101.00 | €116.86 +15.7% | 9.2% | €134.50 | €101.35 | n/a | 8 |
| Dec ’24 | €97.50 | €116.86 +19.9% | 9.2% | €134.50 | €101.35 | n/a | 8 |
| Nov ’24 | €90.50 | €116.86 +29.1% | 9.2% | €134.50 | €101.35 | €62.50 | 8 |
| Oct ’24 | €95.50 | €129.12 +35.2% | 5.8% | €137.29 | €116.46 | €64.00 | 8 |
| Sep ’24 | €102.00 | €124.82 +22.4% | 5.6% | €132.21 | €112.15 | €66.50 | 9 |
| Aug ’24 | €109.00 | €124.82 +14.5% | 5.6% | €132.21 | €112.15 | €61.50 | 9 |
| Jul ’24 | €125.00 | €119.49 -4.4% | 5.8% | €130.69 | €111.09 | €64.00 | 9 |
| Jun ’24 | €113.00 | €117.95 +4.4% | 5.4% | €129.46 | €110.04 | €69.50 | 9 |
| May ’24 | €113.00 | €114.31 +1.2% | 4.4% | €122.47 | €107.96 | €62.50 | 8 |
| Apr ’24 | €94.00 | €103.42 +10.0% | 8.7% | €114.89 | €88.94 | €74.00 | 8 |
| Mar ’24 | €90.50 | €103.90 +14.8% | 6.9% | €113.01 | €92.63 | €74.00 | 6 |
| Feb ’24 | €87.50 | €95.40 +9.0% | 8.4% | €102.52 | €78.79 | €78.50 | 6 |
| Jan ’24 | €82.50 | €95.40 +15.6% | 8.4% | €102.52 | €78.79 | €101.00 | 6 |
| Dec ’23 | €78.50 | €95.13 +21.2% | 8.4% | €104.31 | €80.16 | €97.50 | 6 |
| Nov ’23 | €80.50 | €96.15 +19.4% | 8.4% | €108.36 | €83.27 | €90.50 | 6 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
CVS Health
US$69.3b
Provides health solutions in the United States.
CVS
US$50.67
7D
-4.0%
1Y
-19.2%
Fagron
€1.4b
A pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide.
4A5
€18.54
7D
-1.2%
1Y
9.3%
Shandong Weigao Group Medical Polymer
HK$20.4b
Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.
UK2
HK$0.53
7D
-9.5%
1Y
-41.3%